Jude Onyia Sells 11,000 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction on Monday, June 1st. The stock was sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the transaction, the insider owned 25,846 shares in the company, valued at $4,141,821.50. The trade was a 29.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jude Onyia also recently made the following trade(s):

• On Wednesday, May 27th, Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $155.53, for a total value of $1,710,830.00.

Neurocrine Biosciences Stock Up 6.6%

Shares of NASDAQ NBIX opened at $165.11 on Thursday. The stock has a market capitalization of $16.60 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 1.16 and a beta of 0.40. The stock’s fifty day simple moving average is $141.29 and its 200 day simple moving average is $139.38. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $165.81.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NBIX shares. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Tuesday, April 21st. Royal Bank Of Canada raised their target price on Neurocrine Biosciences from $180.00 to $183.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. Sanford C. Bernstein began coverage on Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price for the company. BMO Capital Markets decreased their target price on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research report on Thursday, February 12th. Finally, Citigroup raised their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $187.52.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Nilsine Partners LLC acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at $1,197,000. Ruffer LLP acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at $2,479,000. Korea Investment CORP boosted its position in Neurocrine Biosciences by 94.3% during the third quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock valued at $10,064,000 after purchasing an additional 34,800 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Neurocrine Biosciences by 2.4% during the third quarter. Envestnet Asset Management Inc. now owns 202,846 shares of the company’s stock valued at $28,476,000 after purchasing an additional 4,807 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in Neurocrine Biosciences by 17,250.0% during the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock valued at $1,120,000 after purchasing an additional 7,935 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.